- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Sarcopenia increased the risk of renal toxicity in bladder cancer patients: Study

A new study published in the British Journal of Urology International found that sarcopenia was linked to increased the risk of neoadjuvant chemotherapy (NAC)-associated renal toxicity in patients with muscle-invasive bladder cancer (MIBC). It may also raise the risk of renal toxicity in individuals with questionable renal function.
There is evidence that individuals with sarcopenia or muscular deficiencies may not benefit from the existing techniques of evaluating renal function using creatinine-based equations. For instance, creatinine-based estimations significantly overestimated renal function in a previous study of individuals with neurogenic lower urinary tract impairment. Therefore, Eiftu Haile and colleagues carried out this study to determine whether borderline renal function (estimated glomerular filtration rate [eGFR] 40-65 mL/min) modifies the effect of sarcopenia on neoadjuvant chemotherapy toxicity and whether sarcopenia and borderline renal function have an independent relationship with NAC toxicity risk.
All patients with MIBC who had radical cystectomies (RCs) between 2010 and 2022 and had cross-sectional imaging accessible before NAC treatment were included. Using Aquarius Intuition software, skeletal mass was calculated from axial computed tomography scans taken at the level of the L3 vertebral body. Based on agreed-upon standards of the skeletal mass index, sarcopenia was allocated. Version 5.0 of the Common Terminology Criteria for Adverse Events was used to rate the toxicity of NAC. The predictors of renal damage linked to NAC were found using binary logistic regression.
There were 216 patients in all and gemcitabine/cisplatin NAC was administered to 76% of individuals with sarcopenia (83%). A substantial risk of renal-associated NAC toxicity was linked to sarcopenia in an unadjusted model (odds ratio [OR] 4.88, 95% confidence interval [CI] 1.65-14.44; P = 0.004).
The OR for renal toxicity with sarcopenia among patients with eGFR 40-65 mL/min was 8.46 (95% CI 1.06-67.72) compared to 3.11 (95% CI 0.81-11.88) among patients with normal renal function (P = 0.43), according to an effect modification model assessing the relationship between sarcopenia and renal function.
Overall, for patients with muscle-invasive bladder cancer, neoadjuvant cisplatin-based chemotherapy is still the standard of care, followed by radical cystectomy. For individuals with MIBC, cisplatin also plays a significant role in trimodality treatment. Although a glomerular filtration rate (GFR) > 60 mL/min has historically been regarded as a cutoff for therapy, individuals with a GFR of 50–60 can still get treatment, albeit with a possibly higher risk of treatment toxicity.
Source:
Haile, E. S., Lone, Z., Shin, D., Nowacki, A. S., Soputro, N., Harris, K., Campbell, R. A., Wood, A., Haywood, S. C., Eltemamy, M., Haber, G.-P., Weight, C. J., Wood, H. M., Taliercio, J. J., Nizam, A., Gupta, S., Remer, E. M., & Almassi, N. (2025). Sarcopenia may increase cisplatin toxicity in bladder cancer patients with borderline renal function. BJU International, 135(5), 775–781. https://doi.org/10.1111/bju.16606
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751